(Q39668407)

13 September 2017

title

Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer (English)

1 reference

13 September 2017

Gaetano Zafarana

2

0 references

Michael Milosevic

object named as

Michael Milosevic

13

0 references

Robert G. Bristow

object named as

Robert G Bristow

14

0 references

Igor Jurišica

10

object named as

Igor Jurisica

1 reference

13 September 2017

Jennifer A Locke

1

1 reference

13 September 2017

Chad A Malloff

3

1 reference

13 September 2017

Wan L Lam

4

1 reference

13 September 2017

Jenna Sykes

5

1 reference

13 September 2017

Melania Pintilie

6

1 reference

13 September 2017

Varune Rohan Ramnarine

7

1 reference

13 September 2017

Alice Meng

8

1 reference

13 September 2017

Omer Ahmed

9

1 reference

13 September 2017

Emma Tomlinson Guns

11

1 reference

13 September 2017

Theo van der Kwast

12

1 reference

13 September 2017

publication date

27 December 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

72

1 reference

13 September 2017

issue

12

1 reference

13 September 2017

page(s)

1295-1305

1 reference

Accuracy of the Kattan nomogram across prostate cancer risk-groups.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

An overview on 5alpha-reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Integrating copy number polymorphisms into array CGH analysis using a robust HMM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

SeeGH--a software tool for visualization of whole genome array comparative genomic hybridization data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Dutasteride: novel milestones in prostate cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: immunohistochemical and real-time PCR studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22478

21 January 2018

Identifiers

DOI

10.1002/PROS.22478

1 reference

13 September 2017

1 reference